Kusho ukuthini ukusebenza ngempumelelo komgomo we-corona?

Ukusebenza komgomo we-COVID-19 ovela kwa-Pfizer ngama-95%, iModerna ingama-94%, kanti uJohnson & Johnson angama-66%, kodwa asho ukuthini la maphesenti?

Ngokusho kwe-LiveScience, akuwona nje umbuzo wezemfundo, indlela oqondwa ngayo akuyona ochwepheshe Lezi zinombolo zithinta kakhulu imibono kanye nezinqumo zabo mayelana nokuthola umgomo, kanye nezinga lokuzinikela kwabo ezinyathelweni zokuphepha ngemva kokugoma, futhi imiphumela yalokhu kuqonda ibonakala ekuthuthukiseni izindlela zokuvimbela ukusabalala kwalolu bhubhane ngezinga elikhulu.

Ebhekisela kumgomo we-Pfizer, uSolwazi Brian Parker, udokotela wezifo ezibangelwa amagciwane e-Drew University eNew Jersey, uzwakalise inkolelo yakhe yokuthi “kubalulekile ukuqonda ukuthi umuthi wokugoma osebenza kahle kakhulu. Nokuthi ukusebenza kwawo kungaphezulu kakhulu kunalokho abanye abangakucabanga, ”ephawula ukuthi inkolelo yokuthi ukusebenza kahle kwama-95% kusho ukuthi ngesikhathi sokuhlolwa komtholampilo okwenziwa yi-Pfizer, u-5% walabo abathole lo mgomo bachayeka esifweni se-Covid-19, ukungaqondi okuvamile.

Incazelo efanele ukuthi iphesenti langempela labantu, ezivivinyweni ze-Pfizer noma zeModerna, abangenwa i-COVID-19 lingu-0.04%, okungaphansi ngokuphindwe ngekhulu kulowo mbono oyiphutha. Okushiwo u-95% ukuthi abantu abagonyiwe babenengozi ephansi engama-95% yokuthola i-COVID-19 kuneqembu elilawulayo, okusho ukuthi abantu abangagonywanga ezivivinyweni zomtholampilo. Ngamanye amazwi, imiphumela yokuhlolwa kwemitholampilo yomgomo we-Pfizer yabonisa ukuthi labo abathole umgomo babesengozini ephindwe ka-20 yokuba nokutheleleka kuneqembu elilawulayo.

Ungathuthukisa kanjani ukusebenza komgomo weCorona

Kungcono kunomuthi wokugomela isimungumungwane nomkhuhlane

USolwazi Parker wengeze ngokuthi lokhu kucaciswa kukhombisa ukuthi umgomo, ngokwemiphumela yokuhlolwa komtholampilo, “ungomunye wemithi yokugoma ephumelela kakhulu.” Uma kuqhathaniswa, umuthi wokugomela i-MMR wemithamo emibili usebenza ngo-97% uma ulwa nesimungumungwane futhi usebenza ngo-88% ngokumelene nomvukuzane, ngokusho kwedatha ye-CDC. Umuthi wokugomela umkhuhlane wesizini uyasebenza futhi phakathi kuka-40% no-60% (ukusebenza kuyahlukahluka unyaka nonyaka, kuye ngokuthi umgomo walowo nyaka kanye nezinhlobo zomkhuhlane), kodwa usavimbela, isibonelo, izigameko ezilinganiselwa ezigidini ezingu-7.5 zomkhuhlane e-United States. I-United States phakathi nesizini yomkhuhlane ka-2019-2020, ngokusho kwe-CDC.

Ngakho-ke, uma ukuphumelela kusho ukwehlisa amacala e-COVID-19 ngephesenti elincane, kufanelekile futhi ukuqaphela incazelo yalokho okungase kuthathwe “njengecala le-COVID-19, njengoba bobabili uPfizer kanye neModerna belichaza njengecala elingabonisa okungenani. uphawu olulodwa.” (noma ngabe imnene kangakanani) umphumela wokuhlolwa oqondile we-PCR. UJohnson & Johnson bachaze 'icala' njengomphumela we-PCR smear, kanye nokungenani uphawu olulodwa olumaphakathi (njengokuphelelwa umoya, amazinga e-oksijini egazi elingavamile, noma izinga lokuphefumula elingavamile) noma izimpawu ezimbili ezingathi shu. , ukukhathala, ikhanda elibuhlungu, isicanucanu).

Inkinga yokuqhathanisa

Umuntu onecala elincane le-COVID-19, ngokwale ncazelo, angathinteka kancane noma ahlale embhedeni futhi agule amasonto ambalwa.

Lapha kuvela enye inkinga ekuqhathaniseni ukusebenza kahle kwemithi yokugoma enye nenye, njengoba uSolwazi Parker echaza ukuthi kunzima ukuqhathanisa ukusebenza ngqo phakathi kwemithi yokugomela i-Pfizer, iModerna kanye ne-Johnson & Johnson, uma sibala embalwa, ngoba ukuhlolwa kwemitholampilo kwenzeka ezindaweni ezahlukene. izindawo ezinamaqembu ahlukene abantu, futhi ezikhathini ezihluke kancane enkathini yobhubhane futhi kusho ukuthi kukhona ukuguqulwa okuhlukile ngesikhathi socwaningo ngalunye.

USolwazi Parker wengeze wathi, "Baningi abantu abangenwe yi-B117 [uguquko olujikeleza e-UK] noma ezinye izinhlobo zezinkinga noguquko ngesikhathi sokuqulwa kwecala likaJohnson & Johnson kunangesikhathi sokuqulwa kwecala leModerna."

Ukuvikelwa kwezimpawu

Futhi akukho nesisodwa isivivinyo sokugoma kokuthathu esake sahlola iziguli ezi-asymptomatic COVID-19. USolwazi Parker uthe: "Zonke izibalo ezisebenzayo zibonisa ukuvikela ekuqalekeni kwezimpawu, hhayi ukuvikela ekuthelelekeni." (Olunye ucwaningo lwakuqala luphakamisa ukuthi imigomo ye-Pfizer kanye neModerna iphinde yehlise inani lezinhlayiya zegciwane emzimbeni womuntu, ezibizwa nge-viral load, kanye namathuba okuba kuhlolwe ukuthi unayo, enciphisa ukusulelana.) Kodwa kusenesidingo sokuqinisekisa ukunemba lezi zifundo kanye nemiphumela NgokukaSolwazi uParker, labo abajovwe ngomjovo abanakuyeka ukugqoka imaski yokuzivikela futhi balandele zonke ezinye izinyathelo zokuphepha.

Kepha zontathu lezi zivivinyo ziphinde zasebenzisa incazelo yesibili 'yezimo zokutheleleka', okungenzeka kubaluleke kakhulu, njengoba umbandela onquma kakhulu ukusebenza kahle nokuvikela ezinkingeni ezimbi kakhulu ze-COVID-19. Ngakho-ke, lezi zinkampani ezintathu ziphinde zalinganisa ukusebenza kwemithi yazo yokugoma ezimweni ezinzima, okusho ukuthi inhliziyo enzima noma izinga lokuphefumula elithintekile kanye/noma isidingo sokuthola umoya-mpilo owengeziwe, ukungeniswa kokunakekelwa okujulile, ukwehluleka ukuphefumula noma ukufa.

100% ukuvikela ukufa

Yomithathu imithi yokugoma ibisebenza ngo-100% ekuvimbeleni isifo esibi kakhulu emasontweni ayisithupha ngemva komthamo wokuqala (i-Moderna) noma amasonto ayisikhombisa ngemva komthamo wokuqala (ku-Pfizer no-Johnson & Johnson, njengoba lo mgomo uqukethe umthamo owodwa kuphela) Akekho noyedwa kubantu owagonywa. ukuze balaliswe esibhedlela, futhi akukho ukushona kwabantu abavela ku-COVID-19 okurekhodiwe, ngemuva kokuthi imigomo iqale ukusebenza ngokugcwele. “Sinenhlanhla emangalisayo ngendlela le mithi yokugoma esebenza ngayo,” kuphetha uSolwazi Parker.